Timing is everything.

 Speaking of gliomas (high grade, in this case), what is the optimal timing of post-treatment surveillance imaging? The frequency of imaging is largely driven by clinical gestalt and schedules from trial protocols. This study looked at >250 patients from a single institution treated for GBM and AA to determine the optimal timing of surveillance imaging based on a criterion of 10% risk of progression among the population of patients still under surveillance. For IDH-wt GBM, the optimal timing was every 7.4 weeks for the first ~2 years then ~6 months thereafter. For IDH-mut GBM, optimal frequency was every 13.2 weeks. For IDH-wt AA, optimal frequency was 22.8 weeks, and for IDH-mut AA, the optimal frequency was every 41.2 weeks. | Ji, Neuro Oncol 2021